Surveillance for severe influenza, COVID-19, and RSV in patients admitted to sentinel Australian hospitals in 2025: the Influenza Complications Alert Network (FluCAN) and the Paediatric Active Enhanced Disease Surveillance (PAEDS) system
Communicable Diseases Intelligence · 2026
DOI: 10.33321/cdi.2026.50.058 ↗Kurz gefasst
Fachartikel in der Zeitschrift Communicable Diseases Intelligence, 2026. Verfasst von Hannah Morgan und 29 weiteren Autor:innen. Beteiligte Einrichtung: Epidemiology Research Fellow, Monash Health and School of Clinical Sciences, Monash University. Hauptthemen laut MEDLINE: COVID-19, Influenza, Human, Respiratory Syncytial Virus Infections, Sentinel Surveillance. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
IntroductionInfluenza, coronavirus disease 2019 (COVID-19) and respiratory syncytial virus (RSV) are common acute respiratory infections and are a cause of significant morbidity and mortality. This report summarises the epidemiology of hospitalisations with laboratory-confirmed influenza, COVID-19 and RSV in 2025 in an Australian sentinel surveillance system. MethodsThe Influenza Complications Alert Network (FluCAN) and the Paediatric Active Enhanced Disease Surveillance (PAEDS) are collaborative sentinel hospital-based surveillance programs that operate at 23 sites across all jurisdictions in Australia. Influenza, COVID-19 and RSV patients were defined as those hospitalised due to an acute respiratory infection at the sentinel hospitals with virus confirmation by nucleic acid detection. ResultsIn 2025, there were 8,749 hospitalisations of patients with influenza; 3,501 with COVID-19; and 5,105 with RSV reported at the 23 sentinel hospitals. Of patients hospitalised with influenza, 4,397 (50.3%) were children (< 16 years of age); 697 (8.0%) were Aboriginal and/or Torres Strait Islander people; and 5,020 (57.4%) had chronic comorbidities. The mean length of hospital stay for patients with influenza was 4.4 days (median: 2 days). Influenza hospital admissions peaked nationally in epidemiological week 28. Influenza vaccine effectiveness against hospitalisation with any influenza type/subtype was estimated at 43% (95% confidence interval [95% CI]: 39–48%) and was highest for influenza B (75% [95% CI: 69–80%]), and lowest for influenza A H3N2 including subclade K (30.5% [95% CI: 15.0–43.2%]). Of patients hospitalised with COVID-19, 1,057 (30.2%) were children (< 16 years of age); 230 (6.6%) were Aboriginal and/or Torres Strait Islander people; and 2,544 (72.7%) had chronic comorbidities. The mean length of hospital stay for patients with COVID-19 was 7 days (median: 3 days). COVID-19 hospital admissions peaked nationally in week 26. In adults ≥ 75 years of age, the relative risk of hospitalisation was 40% (95% CI: 25–52%) lower in those who had received a COVID-19 vaccine within 180 days, compared to those vaccinated > 1 year prior to admission. Of patients hospitalised with RSV, 1,551 (30.4%) were infants (< 1 year of age) and 3,723 (72.9%) were young children (< 5 years of age); 348 (6.8%) were Aboriginal and/or Torres Strait Islander people; and 2,110 (41.3%) had chronic comorbidities. The mean length of hospital stay for patients with RSV was 3.5 days (median: 2 days). There was a peak in activity in week 28. DiscussionSince 2022, influenza, RSV and COVID-19 have co-circulated. In 2025, disease severity—as indicated by average length of stay and proportions admitted to intensive care—was similar in patients hospitalised with any of the three pathogens. Assessment of vaccine effectiveness demonstrated protection against influenza hospitalisation and short-term protection against hospitalisation with COVID-19 in older people.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Epidemiology Research Fellow, Monash Health and School of Clinical Sciences, Monash University.
- Clinical Professor, University of Sydney and Westmead Hospital.
- Professor, Adelaide University; Respiratory and Sleep Medicine Specialist, Royal Adelaide Hospital.
- Professor and Respiratory Physician, Royal Melbourne Hospital and University of Melbourne.
- Head of Unit for Respiratory Medicine and Sleep Disorders, Royal Melbourne Hospital and University of Melbourne.
- Respiratory Physician, Cairns Base Hospital.
Zitieren
APA
Morgan, H., Dwyer, D., Holmes, M., Irving, L., Rees, M., Vincent, S., Chiong, F., Marr, I., Korman, T., Bartolo, C., Cooley, L., Bowler, S., Kok, J., Runnegar, N., Fatovich, D., Waterer, G., Macartney, K., Crawford, N., Bellamy, K., …, & Cheng, A. (2026). Surveillance for severe influenza, COVID-19, and RSV in patients admitted to sentinel Australian hospitals in 2025: the Influenza Complications Alert Network (FluCAN) and the Paediatric Active Enhanced Disease Surveillance (PAEDS) system. Communicable Diseases Intelligence. https://doi.org/10.33321/cdi.2026.50.058
Vancouver
Morgan H, Dwyer D, Holmes M, Irving L, Rees M, Vincent S, et al. Surveillance for severe influenza, COVID-19, and RSV in patients admitted to sentinel Australian hospitals in 2025: the Influenza Complications Alert Network (FluCAN) and the Paediatric Active Enhanced Disease Surveillance (PAEDS) system. Communicable Diseases Intelligence. 2026. doi:10.33321/cdi.2026.50.058
BibTeX
@article{Morgan2026,
author = {Morgan, Hannah and Dwyer, Dominic and Holmes, Mark and Irving, Louis and Rees, Megan and Vincent, Stephen and Chiong, Fabian and Marr, Ian and Korman, Tony and Bartolo, Caroline and Cooley, Louise and Bowler, Simon and Kok, Jen and Runnegar, Naomi and Fatovich, Daniel and Waterer, Grant and Macartney, Kristine and Crawford, Nigel and Bellamy, Karen and Carr, Jeremy and Marshall, Helen and Clark, Julia and Francis, Joshua and McMullan, Brendan and Britton, Philip and Wood, Nicholas and Kotsimbos, Tom and Kelly, Paul and Blyth, Christopher and Cheng, Allen},
title = {Surveillance for severe influenza, COVID-19, and RSV in patients admitted to sentinel Australian hospitals in 2025: the Influenza Complications Alert Network (FluCAN) and the Paediatric Active Enhanced Disease Surveillance (PAEDS) system},
journal = {Communicable Diseases Intelligence},
year = {2026},
doi = {10.33321/cdi.2026.50.058}
}
EUVIMED